Role of nuclear factor-κB regulators TNFAIP3 and CARD11 in Middle Eastern diffuse large B-cell lymphoma

References

• Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005;106:1164–1174.
   PubMed Web of Science ®Google Scholar
• Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases. Br J Haematol 2004;124:151–159.
   PubMed Web of Science ®Google Scholar
• Bazarbashi S. Cancer Incidence Report, Saudi Arabia, 2004. Riyadh: Saudi Cancer Registry; 2008.
   Google Scholar
• Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 2005;87: 163–208.
   PubMed Web of Science ®Google Scholar
• Basseres DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25:6817–6830.
   PubMed Web of Science ®Google Scholar
• Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007;109:2700–2707.
   PubMed Web of Science ®Google Scholar
• Cilloni D, Martinelli G, Messa F, . Nuclear factor kB as a target for new drug development in myeloid malignancies. Haematologica 2007;92:1224–1229.
   PubMed Web of Science ®Google Scholar
• Dutta J, Fan Y, Gupta N, . Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006;25: 6800–6816.
   PubMed Web of Science ®Google Scholar
• Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest 2005;115:2625–2632.
   PubMed Web of Science ®Google Scholar
• Burstein E, Duckett CS. Dying for NF-kappaB? Control of cell death by transcriptional regulation of the apoptotic machinery. Curr Opin Cell Biol 2003;15:732–737.
   PubMed Web of Science ®Google Scholar
• Greten FR, Eckmann L, Greten TF, . IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285–296.
   PubMed Web of Science ®Google Scholar
• Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006;441:431–436.
   PubMed Web of Science ®Google Scholar
• Lawrence T, Bebien M, Liu GY, . IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 2005;434:1138–1143.
   PubMed Web of Science ®Google Scholar
• Compagno M, Lim WK, Grunn A, . Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009;459:717–721.
   PubMed Web of Science ®Google Scholar
• Bavi P, Uddin S, Bu R, . The biological and clinical impact of inhibition of NF-κB initiated apoptosis in diffuse large B-cell lymphoma (DLBCL). J Pathol 2011;224:355–366.
   PubMed Web of Science ®Google Scholar
• Bertin J, Wang L, Guo Y, . CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J Biol Chem 2001;276:11877–11882.
   PubMed Web of Science ®Google Scholar
• Gaide O, Martinon F, Micheau O, . Carma1, a CARD-containing binding partner of Bcl10, induces Bcl10 phosphorylation and NF-kappaB activation. FEBS Lett 2001;496:121–127.
   PubMed Web of Science ®Google Scholar
• Wang D, You Y, Case SM, . A requirement for CARMA1 in TCR-induced NF-kappa B activation. Nat Immunol 2002;3:830–835.
   PubMed Web of Science ®Google Scholar
• Rawlings DJ, Sommer K, Moreno-Garcia ME. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nat Rev Immunol 2006;6:799–812.
   PubMed Web of Science ®Google Scholar
• Lenz G, Davis RE, Ngo VN, . Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008;319:1676–1679.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright GW, Emre NC, . Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520–13525.
   PubMed Web of Science ®Google Scholar
• Coornaert B, Carpentier I, Beyaert R. A20: central gatekeeper in inflammation and immunity. J Biol Chem 2009;284:8217–8221.
   PubMed Web of Science ®Google Scholar
• Lee EG, Boone DL, Chai S, . Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000;289:2350–2354.
   PubMed Web of Science ®Google Scholar
• Wertz IE, O’Rourke KM, Zhou H, . De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004;430:694–699.
   PubMed Web of Science ®Google Scholar
• Honma K, Tsuzuki S, Nakagawa M, . TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of NHLs. Blood 2009;114:2467–2475.
   PubMed Web of Science ®Google Scholar
• Kato M, Sanada M, Kato I, . Frequent inactivation of A20 in B-cell lymphomas. Nature 2009;459:712–716.
   PubMed Web of Science ®Google Scholar
• Chanudet E, Huang Y, Ichimura K, . A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma. Leukemia 2010;24:483–487.
   PubMed Web of Science ®Google Scholar
• Novak U, Rinaldi A, Kwee I, . The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009;113: 4918–4921.
   PubMed Web of Science ®Google Scholar
• Schmitz R, Hansmann ML, Bohle V, . TNFAIP3 (A20) is a tumor suppressor gene in Hodgkin lymphoma and primary mediastinal B cell lymphoma. J Exp Med 2009;206:981–989.
   PubMed Web of Science ®Google Scholar
• Chanudet E, Ye H, Ferry J, . A20 deletion is associated with copy number gain at the TNFA/B/C locus and occurs preferentially in translocation-negative MALT lymphoma of the ocular adnexa and salivary glands. J Pathol 2009;217:420–430.
   PubMed Web of Science ®Google Scholar
• Honma K, Tsuzuki S, Nakagawa M, . TNFAIP3 is the target gene of chromosome band 6q23.3-q24.1 loss in ocular adnexal marginal zone B cell lymphoma. Genes Chromosomes Cancer 2008;47: 1–7.
   PubMed Web of Science ®Google Scholar
• Adam P, Haralambieva E, Greiner A, . CARMA1 and chromosomal translocations in extranodal marginal zone B-cell lymphomas of MALT type or diffuse large B-cell lymphomas. Haematologica 2006; 91:1575–1576.
   PubMed Web of Science ®Google Scholar
• Egawa T, Albrecht B, Favier B, . Requirement for CARMA1 in antigen receptor-induced NF-kappa B activation and lymphocyte proliferation. Curr Biol 2003;13:1252–1258.
   PubMed Web of Science ®Google Scholar
• Pappu BP, Lin X. Potential role of CARMA1 in CD40-induced splenic B cell proliferation and marginal zone B cell maturation. Eur J Immunol 2006;36:3033–3043.
   PubMed Web of Science ®Google Scholar
• Re D, Hartlapp I, Greiner A, . Analysis of CARMA1/BCL10/MALT1 expression in Reed-Sternberg cells of classical Hodgkin lymphoma. Leuk Lymphoma 2008;49:362–364.
   PubMed Web of Science ®Google Scholar
• Schumacher MA, Schmitz R, Brune V, . Mutations in the genes coding for the NF-kappaB regulating factors IkappaBalpha and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma. Haematologica 2010;95:153–157.
   PubMed Web of Science ®Google Scholar
• Durkop H, Hirsch B, Hahn C, . Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation. J Pathol 2003;200:229–239.
   PubMed Web of Science ®Google Scholar
• Bavi P, Prabhakaran SE, Abubaker J, . Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations. Mol Cancer 2010;9:203.
   PubMed Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, ., editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001. pp 10–12.
   Google Scholar
• Bavi P, Abubaker J, Hussain A, . Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Hum Pathol 2008;39:885–894.
   PubMed Web of Science ®Google Scholar
• Montagut C, Tusquets I, Ferrer B, . Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006;13:607–616.
   PubMed Web of Science ®Google Scholar
• Charalambous MP, Lightfoot T, Speirs V, . Expression of COX-2, NF-kappaB-p65, NF-kappaB-p50 and IKKalpha in malignant and adjacent normal human colorectal tissue. Br J Cancer 2009;101: 106–115.
   PubMed Web of Science ®Google Scholar
• Legrand-Poels S, Schoonbroodt S, Piette J. Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line. Biochem J 2000;349:765–773.
   PubMed Web of Science ®Google Scholar
• McCarty KS Jr, Miller LS, Cox EB, . Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985;109:716–721.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252–7259.
   PubMed Web of Science ®Google Scholar
• Jehan Z, Bavi P, Sultana M, . Frequent PIK3CA gene amplification and its clinical significance in colorectal cancer. J Pathol 2009;219:337–346.
   PubMed Web of Science ®Google Scholar
• Robledo C, Garcia JL, Caballero D, . Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. Cancer 2009;115:3728–3737.
   PubMed Web of Science ®Google Scholar
• Oshiro A, Tagawa H, Ohshima K, . Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood 2006;107:4500–4507.
   PubMed Web of Science ®Google Scholar
• Fujiwara SI, Yamashita Y, Nakamura N, . High-resolution analysis of chromosome copy number alterations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified, with single nucleotide polymorphism-typing microarrays. Leukemia 2008;22:1891–1898.
   PubMed Web of Science ®Google Scholar
• Narayan P, Holt B, Tosti R, . CARMA1 is required for Akt-mediated NF-kappaB activation in T cells. Mol Cell Biol 2006;26: 2327–2336.
   PubMed Web of Science ®Google Scholar
• Dong G, Chanudet E, Zeng N, . A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma. Clin Cancer Res 2011;17:1440–1451.
   PubMed Web of Science ®Google Scholar
• Montesinos-Rongen M, Schmitz R, Brunn A, . Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol 2010;120:529–535.
   PubMed Web of Science ®Google Scholar
• Naylor TL, Tang H, Ratsch BA, . Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011;71:2643–2653.
   PubMed Web of Science ®Google Scholar